Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-808-0 | CAS number: 68608-89-9 This substance is identified by SDA Substance Name: C11-C13 branched alkyl benzene sulfonic acid sodium salt and SDA Reporting Number: 25-097-04.
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
80-90% of the analogue substance LAS was absorbed through the gastrointestinal tract. Most of the absorbed LAS was eliminated within 72 hours and 60-65% of the absorbed dose was eliminated in the urine, 35% of the absorbed 35S was excreted in the bile and was reabsorbed completely from the gastrointestinal tract.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 80
- Absorption rate - dermal (%):
- 1
- Absorption rate - inhalation (%):
- 80
Additional information
No specific studies on sodium salt branched alkylate derivatives (BABS Na salt) were available. However, a study is available on analogue linear alkyl benzene sulfonate (LAS). The LAS structure is a C10 -C13 linear alkyl chain with a para-substituted benzene sulfonic acid sodium salt group attached at any of the secondary alkyl chain carbon positions. The alkyl chian length averages 11.6. LAS is structurally similar to BABS Na salt, as both are para C11 -C13 alkylbenzene sulfate sodium salts. The primary difference is whether the alkyl chain is linear or branched. A study of biotransformation and kinetics of BABS Na salt (IUCLID section 6.5) indicates that the microbial biodegradatin pathway of BABS Na salt is similar to that of LAS. Based on similar structures and microbial biodegradation pathways, LAS is a good analogue for read-across for instances where data are availabe on it but not on BABS Na salt.
The absorption, distribution, metabolism and elimination of LAS (radioactively labeled with 35S) were studied in male Charles River rats. LAS was readily absorbed by the gastrointestinal tract and rapidly metabolized and excreted in the urine. Oral and inhalation absorption is considered to be equal. Based on data (IUCLID 7.1.1), the substance is readily absorbed following oral exposure (LAS data show 80-90% absorption). Therefore, there is no need to apply the default Application Factor of 2 based on the assumption that oral absorption is only 50% compared to 100% for inhalation. Based on data from a dermal absorption study of a C12LAS homologue in isolated human epidermis (Howes 1975) that indicated < 0.065% of the applied dose penetrated the skin in 48 hours, 1% dermal absorption is conservatively assumed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
